Preclinical Evaluation of the Multiple Tyrosine Kinases Inhibitor Anlotinib in Leukemia Stem Cells

Leukemia stem cells (LSCs) constitute the critical barrier to the cure of acute myeloid leukemia (AML) due to their chemoresistance and immune evasion property. Herein, the role of anlotinib, a multiple tyrosine kinase inhibitor, in killing LSCs and regulating chemoresistance and immune evasion was...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Yuelong, Liu, Long, Jiang, Yirong, Li, Zhifeng, Feng, Liying, Zhuang, Xinguo, Lin, Zhijuan, Chen, Qiuling, Chen, Guoshu, He, Jixiang, Li, Guowei, Zha, Jie, Xu, Bing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9697152/
https://www.ncbi.nlm.nih.gov/pubmed/36355485
http://dx.doi.org/10.3390/ph15111313

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9697152/
https://www.ncbi.nlm.nih.gov/pubmed/36355485
http://dx.doi.org/10.3390/ph15111313

Ejemplares similares